Nasdaq:APYX
Apyx Medical Corp
Apyx Medical Corp develops specialized electrosurgical platforms enabling precise tissue ablation for oncology and trauma surgeons.
Key Metrics
Investment Thesis
Bull Case
Apyx occupies a protected niche with proprietary technology that faces limited direct competition, offering potential for margin expansion as market share grows. If the company can streamline its cost structure and reduce operating expenses below $48.2M, it could achieve breakeven within the next fiscal cycle. Strategic partnerships with major hospital systems provide predictable revenue visibility and leverage for future acquisitions or licensing deals.
Bear Case
The company has posted consecutive years of substantial net losses, signaling fundamental business model issues that threaten long-term survival. High debt obligations relative to current assets create vulnerability in a tightening credit environment where refinancing may not be available on favorable terms. Without a clear path to profitability or a major strategic pivot, the stock faces significant downside risk as investors demand higher returns for equity of a distressed firm.
About Apyx Medical Corp
Apyx Medical Corp designs, manufactures, and markets electrosurgical technologies for surgical applications across hospital systems and ambulatory surgery centers. The company focuses on bipolar electrosurgical generators that provide precise hemostasis while minimizing tissue damage, primarily serving the U.S. healthcare market. Key products include the Apyx Harmonic™ system used in complex procedures like cancer ablation and trauma care.
Analysis
Management Discussion
Despite a revenue increase from $44.5M in 2022 to $52.3M in 2023, the company returned to a loss of $23.6M in 2024, mirroring the previous year's performance and erasing the prior year's improvement. Cash flow from operations remained negative at $18.0M, while significant non-cash adjustments totaling $8.9M partially offset the cash burn rate. The retention of a large retained earnings deficit of $77.9M highlights ongoing challenges in converting top-line growth into sustainable profitability.
Industry Overview
The electrosurgical device market is fragmented but dominated by established players with broad product portfolios, leaving niche specialists like Apyx to compete on specific clinical indications. Regulatory approval cycles and reimbursement policies in the U.S. healthcare system heavily influence adoption rates for new ablation technologies. Consolidation trends favor larger competitors unless a niche player can demonstrate unique value that justifies premium pricing or exclusive distribution.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $44.5M | $52.3M | $48.1M |
| Cost of Revenue | $15.4M | $18.6M | $18.7M |
| Gross Profit | $29.1M | $33.8M | $29.4M |
| Operating Expenses | $52.7M | $53.7M | $48.2M |
| Operating Income | $-23.6M | $-17.3M | $-18.8M |
| R&D | $4.5M | $4.8M | $5.1M |
| G&A | $20.5M | $22.2M | $18.9M |
| Stock-Based Comp | $6.7M | $5.1M | $4.0M |
| D&A | $890.0K | $692.0K | $599.0K |
| Depreciation | $700.0K | $700.0K | $600.0K |
| Other OpEx | $27.7M | $26.7M | $24.3M |
| Non-Operating Income | $651.0K | $-4.0M | $-4.5M |
| Interest Expense | $15.0K | $2.5M | — |
| Interest Income | — | — | $1.6M |
| Pre-Tax Income | $-22.9M | $-21.3M | $-23.3M |
| Income Tax | $367.0K | $-2.4M | $252.0K |
| Continuing Ops | $-23.3M | $-18.9M | $-23.6M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-23.3M | $-18.9M | $-23.6M |
| Minority Interest | $-94.0K | $-137.0K | $-96.0K |
| Net to Common | $-23.2M | $-18.7M | $-23.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $43.0M | $70.4M | $56.4M |
| Cash & Equivalents | $10.2M | $43.7M | $31.7M |
| Accounts Receivable | $10.6M | $14.0M | $15.5M |
| Inventory | $11.8M | $9.9M | $7.6M |
| Prepaid Expenses | $2.7M | $2.7M | $1.7M |
| Other Current Assets | $7.6M | $30.0K | $0 |
| Long-Term Assets | $8.8M | $8.9M | $8.4M |
| PP&E (Net) | $6.8M | $1.9M | $2.0M |
| Operating Leases | $710.0K | $5.2M | $4.7M |
| Other LT Assets | $1.3M | $1.8M | $1.7M |
| Total Assets | $51.8M | $79.2M | $64.8M |
| Current Liabilities | $11.8M | $12.7M | $10.7M |
| Accounts Payable | $2.7M | $2.7M | $2.6M |
| Current Leases | $216.0K | $347.0K | $335.0K |
| Deferred Revenue | $900.0K | $500.0K | — |
| Other Current Liab | $-863.0K | $9.2M | $20.0K |
| Long-Term Liabilities | $2.1M | $39.6M | $39.8M |
| Long-Term Debt | — | $33.2M | $33.9M |
| LT Operating Leases | $470.0K | $4.9M | $4.5M |
| Other LT Liab | $254.0K | $251.0K | $292.0K |
| Total Liabilities | $14.0M | $52.3M | $50.5M |
| Shareholders' Equity | $37.8M | $26.9M | $14.3M |
| Paid-In Capital | $73.3M | $81.1M | $92.1M |
| Retained Earnings | $-35.7M | $-54.4M | $-77.9M |
| Total L&E | $51.8M | $79.2M | $64.8M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-23.3M | $-18.9M | $-23.6M |
| Non-Cash Adjustments | $63.0K | $18.0M | $8.9M |
| Working Capital Changes | $2.9M | $-4.4M | $-3.4M |
| Cash from Operations | $-20.3M | $-5.2M | $-18.0M |
| Capital Expenditures | $1.0M | $533.0K | $722.0K |
| Cash from Investing | $-1.0M | $6.7M | $-722.0K |
| Debt Issuances | — | $43.5M | $0 |
| Cash from Financing | $217.0K | $32.2M | $6.7M |
| FX Effect | $395.0K | $-191.0K | $113.0K |
| Net Change in Cash | $-20.7M | $33.5M | $-11.9M |
| Beginning Cash | $30.9M | $10.2M | $43.7M |
| Ending Cash | $10.2M | $43.7M | $31.7M |
Frequently Asked Questions
How does Apyx Medical Corp make money?
The company's revenue is derived from the sale of electrosurgical generators, handpieces, and disposable accessories primarily through direct hospital contracts. Operations are segmented by device type and clinical application, with a focus on bipolar technology that differentiates from standard monopolar units. Revenue streams also include recurring consumable sales tied to generator utilization in procedural settings.
What are the main risks for APYX?
Persistent net losses indicate an inability to achieve operational breakeven, raising concerns about long-term capital sustainability without further financing. High levels of debt relative to equity expose the company to refinancing risk if interest rates rise or credit markets tighten. Revenue contraction in 2024 suggests potential cyclicality or payer pressure that could exacerbate cash flow challenges. The niche market size limits growth scalability compared to broader medical device peers.
What is APYX's competitive advantage?
Apyx holds exclusive intellectual property protecting its proprietary bipolar electrosurgical platform, creating a defensible market niche against generic competitors. The company benefits from deep clinical validation across major trauma centers and cancer hospitals, fostering strong physician loyalty and switching costs. Its focused portfolio allows for rapid iteration of disposable components that reduce total cost of ownership for large surgical departments.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.